Cross-reactive neutralizing antibody against pandemic 2009 h1n1 influenza a virus in intravenous immunoglobulin preparations

Pediatric Infectious Disease Journal

Volumn 30, Issue 1, 2011, Pages 67-69

  Hong, David K ^a   Tremoulet, Adriana H ^b   Burns, Jane C ^b   Lewis, David B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

2009 H1N1; influenza A; intravenous immunoglobulin; Kawasaki disease; neutralizing antibody

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; HEMAGGLUTINATION INHIBITING ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CROSS REACTION; DISEASE SEVERITY; DRUG SCREENING; HEMAGGLUTINATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFANT; INFLUENZA VIRUS A H1N1; MUCOCUTANEOUS LYMPH NODE SYNDROME; PANDEMIC; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE;

EID: 78650768501     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f127be     Document Type: Article

References (14)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-2615.
2. Centers for Disease Control and Prevention (CDC). Interim results: state-specific seasonal influenza vaccine coverage-United States, August 2009-January 2010. Morb Mortal Wkly Rep. 2010;59:477-484.
3. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-1944.
4. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospi-talizations in the United States. JAMA. 2004;292:1333-1340.
5. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945-1952.
6. Xu R, Ekiert DC, Krause JC, et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328:357-360.
7. De Jong JC, Palache AM, Beyer WE, et al. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63-73.
8. Lee KY, Han JW, Lee JS, et al. Alteration of biochemical profiles after high-dose intravenous immunoglobulin administration in Kawasaki disease. Acta Paediatr. 2002;91:164-167.
9. Webster R, Cox N, Stohr K. WHO Manual on Animal Influenza Diagnosis and Surveillance. Geneva, Switzerland: World Health Organization; 2002.
10. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937-943.
11. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599-609.
12. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450-1451.
13. Palladino G, Mozdzanowska K, Washko G, et al. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol. 1995;69:2075-2081.
14. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. Morb Mortal Wkly Rep. 2009;58:893-896.